As of Beijing time The data is from a third-party organization and is only for reference.
For actual information, please refer to:www.eastmoney.com
Address: 470 Wildwood Ave, Woburn, MA 01801 (America)
Tel: +1(626)986-9880
Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK
Tel: 0044 7790 816 954
Email: marketing@medicilon.com
Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)
Postcode: 201299
Tel: +86 (21) 5859-1500 (main line)
Fax: +86 (21) 5859-6369
© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3
Shanghai Public Network Security File No. 31011502018888 | Website Map
Business Inquiry
Global:
Email:marketing@medicilon.com
+1(626)986-9880(U.S.)
0044 7790 816 954 (Europe)
China:
Email: marketing@medicilon.com.cn
Tel: +86 (21) 5859-1500
1) Understanding the structural boundaries associated with oral absorption
2) Identifying/determining the cause of poor oral bioavailability within a compound family
3) Using in vitro screening methods
4) The oral administration formula should enhance compound dissolution, and maintain them in a dissolved state at all times; non-precipitating solutions maximize the bioavailability of compounds limited by solubility or dissolution
5) The formulation should be as simple as possible to increase the probability of successful development.
6) For lead compounds that are needed to improve bioavailability, problem-solving strategies should focus to formulation or chemical approaches in parallel